NovaBridge Biosciences (NBP) Receivables - Other (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Receivables - Other for 5 consecutive years, with $2.0 million the latest figure, recorded in Q4 2023.

• Quarterly Receivables - Other rose 70.51% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (up 70.51% YoY) and the FY2023 annual result came in at $2.0 million, changed N/A from the prior year.
• Receivables - Other grew to $2.0 million in Q4 2023 per NBP's latest filing, from $1.2 million in the prior quarter.
• Over the last five years, Receivables - Other for NBP reached as high as $43.5 million in Q2 2022 and fell as low as $1.2 million in Q4 2022.
• A 4-year average of $14.4 million and a median of $7.7 million in 2020 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other plunged 83.9% — and 2023, when it soared 70.51%.
• Year by year, Receivables - Other stood at $7.8 million in 2020, then tumbled by 83.9% to $1.3 million in 2021, then slipped by 8.41% to $1.2 million in 2022, then surged by 70.51% to $2.0 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.0 million, $1.2 million, and $43.5 million for Q4 2023, Q4 2022, and Q2 2022 respectively.